Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR 2021
Shots:
- The AURORA 2 involves assessing Lupkynis vs control arm in 216 patients who have completed P-III AURORA 1 study for 1 year
- Results: reduction in UPCR from pre-treatment baseline to year 2 (-3.1 vs -2.1 mg/mg); reduction proteinuria b/w 1 & 2year (1.0 vs 0.6 mg/mg); stable renal function. In general- the interim analysis of AURORA 2 showed that the patients treated with Lupkynis for up to 2yrs. sustained reductions in proteinuria- with no change in mean eGFR @104wks.
- Additionally- the EULAR presentation will highlight RWE suggesting reduced economic burden to healthcare payers when achieving lower LN disease activity
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com